Karyopharm Therapeutics extends forbearance period to November 1
Karyopharm Therapeutics Inc. extended its forbearance period to November 1, 2026, according to a Form 8-K filed with the U.S. Securities and Exchange Commission on October 22, 2026. The extension moves the deadline for the Forbearance Agreement from October 22, 2026, to 11:59 p.m. Eastern time on November 1, 2026.
Karyopharm Therapeutics Inc. extended its forbearance period to November 1, 2026, according to a Form 8-K filed with the U.S. Securities and Exchange Commission on October 22, 2026. The extension moves the deadline for the Forbearance Agreement from October 22, 2026, to 11:59 p.m. Eastern time on November 1, 2026.
The company, headquartered in Newton, Massachusetts, entered into the Forbearance Agreement and Limited Waiver to Indentures on September 10, 2026. Prior to the latest extension, applicable parties had already extended the forbearance period to October 22, 2026. The most recent change was made in accordance with Section 19 of the agreement.
Karyopharm previously disclosed the initial agreement in Current Reports on Form 8-K filed on September 11, 2026, and October 14, 2026. The new filing indicates that the forbearance period will end on November 1, 2026, absent earlier termination. Michael Mano, Executive Vice President, Chief Legal Officer and Secretary of Karyopharm Therapeutics Inc., signed the report on behalf of the company.
The company’s common stock trades on the Nasdaq Global Select Market under the ticker symbol KPTI. Karyopharm is incorporated in Delaware and has a Commission File Number of 001-36167. The filing does not specify the reasons for the extension or details regarding the financial terms of the indentures beyond the dates and agreement sections referenced.